Press Releases & Author Interviews
-
How Two Russian Scientists Changed the Way We Understand Aging and Cancer
A new essay was published in Volume 17, Issue 11 of Aging-US on November 19, 2025, titled “On the intergenerational transfer of ideas in aging and cancer research: from the hypothalamus according to V.M. Dilman to the mTOR protein complex according to M.V. Blagosklonny.”
-
Machine Learning Identifies Senescence-Inducing Compound for p16-Positive Cancer Cells
A new research paper featured on the cover of Volume 17, Issue 11 of Aging-US was published on October 30, 2025, titled “SAMP-Score: a morphology-based machine learning classification method for screening pro-senescence compounds in p16 positive cancer cells.” … continue reading
-
Hospital Infections Associated with Higher Risk of Dementia
A new research paper was published in Volume 17, Issue 10 of Aging-US on October 13, 2025, titled “Hospitalization with infections and risk of Dementia: a systematic review and meta-analysis.” … continue reading
-
Embryo Arrest in IVF Linked to Maternal Age, Not Chromosomal Abnormalities
A new research paper was published in Volume 17, Issue 10 of Aging-US on October 10, 2025, titled “Developmental arrest rate of an embryo cohort correlates with advancing reproductive age, but not with the aneuploidy rate of the resulting blastocysts in good prognosis patients: a study of 25,974 embryos.” … continue reading
Aging-US: Volume 17, Issue 11
-
SAMP-Score: a morphology-based machine learning classification method for screening pro-senescence compounds in p16 positive cancer cells
Senescence identification is rendered challenging due to a lack of universally available biomarkers. This represents a bottleneck in efforts to develop pro-senescence therapeutics – agents designed to induce the arrest of cellular proliferation associated with a senescence response in cancer cells for therapeutic gain.
Aging Blogs
ABOUT Dr. Mikhail (Misha) Blagosklonny:
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time.
Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy.
Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true.
In Remembrance | @Blagosklonny
ABOUT AGING-US.NET
Aging-US.net features press releases on the latest aging research, plus interviews and from the distinguished network of authors who continue to publish their research with Aging-US, a monthly, traditional, peer-reviewed journal with open access, covering all areas of research on aging, including age-related diseases, such as cancer.
The mission of the journal is to serve as a platform for high-quality research that uncovers the cellular, molecular, and systemic processes underlying aging, and translates these insights into strategies to extend healthspan and delay the onset of chronic disease.
We aim to promote: 1) The development of preventative strategies that delay or mitigate age-associated pathologies by modulating key aging mechanisms, 2) the treatment of age-related diseases through interventions that target the aging process itself, and 3) the validation of anti-aging therapies by demonstrating their impact on functional decline and disease onset.
Impact Journals, the publisher of Aging-US, meets the standards of the Wellcome Trust Publisher Requirements and was included in the Wellcome Trust List of Compliant Publishers. Read about our rigorous Scientific Integrity Process.
To learn more, please visit Aging-US.com and connect with us:
Facebook | X | LinkedIn | YouTube | Instagram | Bluesky | Pinterest | SoundCloud
